Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.

The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.